Posttranscriptional regulation of allergic inflammation
Funded at North Carolina State University Raleigh · NIH-11363446 · Data updated 2026-11-12
A small NIH-funded project aims to understand how a specific cellular regulator helps control allergic lung inflammation in people with asthma.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project start | May 11, 2026 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $223,754 |
| NIH project number | 1R21AI199944-01 |
| Project ID | NIH-11363446 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with allergic asthma or allergic inflammation who may benefit from therapies targeting inflammatory pathways.
✕Less likely to help
Patients with non-allergic asthma or other lung conditions may not experience direct benefits from this specific focus on allergic inflammation.
What this research studies
This project explores how the protein Tristetraprolin (TTP) influences allergic lung inflammation at the level of individual cell types. By studying allergens-induced responses, researchers hope to identify ways to modulate inflammation and potentially reduce symptoms for people with allergic asthma. The work involves targeted experiments to uncover cell-specific roles of TTP and how changing its expression might lessen inflammatory signaling. The findings could point toward new strategies to limit granulocyte recruitment and inflammatory mediators in the lungs. Conducted at North Carolina State University, the research will use human-relevant models to inform future therapies.
Why it matters
Potential benefit: If successful, the research could lead to new approaches to reduce airway inflammation and improve symptom control for patients with allergic asthma.
How similar studies have gone: Previous work suggests endogenous regulators like TTP can modulate inflammation, but translating these findings to human therapies remains an area of active investigation.
Where this research is happening
-
North Carolina State University Raleigh
Raleigh, United States Active
Researchers
- Principal investigator: Saini, Yogesh — North Carolina State University Raleigh
- Study coordinator: Saini, Yogesh
Related research
Other NIH-funded projects on the same topics.
-
Brewing anti-toxin drugs using probiotic yeast
A studying team will develop probiotic yeast–based anti-toxin drugs to help treat gut bacterial infections and reduce antibiotic-related complications.
-
Small Ruminant Therapeutic Center to Speed Safe Drugs for Sheep and Goats
A pilot project at a university will help scientists and veterinarians speed up and improve how drugs are tested and approved for sheep and goats.
-
Metabolic effects of PFAS exposure in the Cape Fear Basin (GenX Exposure Study)
This NIH grant studies how PFAS chemicals in drinking water may affect metabolism and weight-related health in adults and children living along the Cape Fear River.
-
Understanding how Fe/2OG enzymes make pharmacophores like cyclopropane, aziridine, and isonitrile groups
A research project at a university aims to uncover how nonheme-iron enzymes create key drug-building rings and groups to help develop better biocatalysts and medicines.
-
Hemostatic B-knob Microgels for Pediatric Bleeding
A kid-friendly hemostatic therapy using age-tuned microgels to stop dangerous bleeding after injury in children.
-
How cyanotoxins may harm nerve cells in ALS
This grant studies how shared toxins from cyanobacteria might worsen nerve damage in people with ALS.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.